Genfit S.A. is a BCorp™ certified biopharmaceutical company specializing in the discovery and development of therapeutic solutions for rare and life-threatening liver diseases with high unmet medical needs. As a pioneer in liver disease research with over two decades of scientific heritage, it focuses primarily on Acute-on-Chronic Liver Failure (ACLF), acute decompensation (AD), and hepatic encephalopathy (HE), advancing four programs with complementary mechanisms of action targeting key pathophysiological pathways. Genfit S.A. also addresses other serious conditions, including cholangiocarcinoma (CCA), urea cycle disorders (UCD), and organic acidemias (OA), alongside a diagnostic franchise for NASH/MASH and ammonia levels. A notable success is elafibranor, discovered and developed by the company, which received accelerated approval as Iqirvo® in 2024 by the FDA, EMA, and MHRA for Primary Biliary Cholangitis (PBC) and is now marketed by partner Ipsen in several countries. With eight therapeutic programs across various development stages and a commitment to ethics, data science, and corporate social responsibility, Genfit S.A. plays a vital role in addressing gaps in treatments for these challenging diseases.